WM is an indolent mature B-cell neoplasm, and the survival outcomes of the patients have improved. However, it may occasionally transform to histologically more aggressive lymphoma, such as diffuse large B-cell lymphoma (DLBCL). Transformation to DLBCL is associated with poor prognosis [3] [4] [5] [6] .
Spleen was enlarged; however, only a fine incorporation of 18 F-fluorodeoxyglucose was observed, and the size was not increased throughout the course ( Fig. 2 A and B) . As the patient was suffering from severe bone pain with elevated levels of serum ALP and LDH and because strong incorporation of 18 F-fluorodeoxyglucose in multiple bones was observed on PET/CT, multiple cancer metastases to the bones was suggested.
BM biopsy demonstrated extensive necrosis ( Fig. 3 A and B) . In addition to the necrotic tissue, small-to-medium-sized WM cells and large lymphoid cells with high N/C ratio were also observed ( Figure 3 C and D). Normal BM cells were rarely observed. Immunohistochemical study demonstrated that both the small-to-medium-sized cells and the larger cells were CD20+ (Fig. 3 E) . Some larger cells were also CD5+ (Fig. 3 F) . In situ hybridization test for Epstein-Barr virus-encoded RNA was negative.
FCM analysis showed that the smaller cells were positive for CD19, CD20, IgD, and λ; partially positive for CD27, CD38, CD43, CD138, and IgM; and negative for CD2, CD3, CD4, CD5, CD8, CD10, CD11c, CD16, CD23, CD25, CD30, CD34, CD56, and k (Fig. 3 G) .
On the other hand, the large cells were positive for CD5, CD19, CD20, and λ and were negative for CD43, CD138, IgD, and IgM (Fig. 3 H) The patient was diagnosed as having CD5-positive DLBCL, which was transformed from CD5-negative WM, and received chemotherapy (48 mg of pirarubicin, 1.6 mg of vincristine sulfate, 800 mg of cyclophosphamide, and 45 mg of PSL for 5 days), which was followed by only transient resolution of the patient's symptoms.
The patient died due to the progression of DLBCL 7 weeks after the present admission, 110 months after the first visit to the hospital.
Discussion
WM is usually an indolent and slowly progressive disease, and the overall survival of patients has improved over the past decade [4] . WM may transform to DLBCL rarely [3] [4] [5] [6] . The interval WM cases express IgM and pan-B markers, such as CD19 and CD20, and are usually negative for CD5, CD10, and CD23 [7] . In the present In our patient, transformation to DLBCL occurred shortly after the third administration of fludarabine. Immune suppression by purine analogues may lead to aggressive transformation because of defects in tumor surveillance [9] . The potential relationship between transformation to high-grade lymphoma and treatment with purine analogues has been controversial [10, 11] . Moreover, histological transformation could occur not only in patients who received chemotherapy with alkylating agents and/or purine analogues but also in treatment-naïve patients [4] . On the other hand, some antineoplastic drugs such as fludarabine may cause BM necrosis [12] . However, in the present case, extremely elevated sIL-2R level was observed when the patient suffered from BM necrosis, suggested that the rapidly progressive DLBCL was the underlying cause of BM necrosis. WM is incurable with currently available chemotherapy, and there is no standard therapy. Alkylating agents and purine analogues are the most commonly used agents. Our case was an indolent outpatient and preferred oral administration of fludarabine [11, 13] .
Recently, however, combination chemotherapy regimens containing rituximab are recommended for first-line therapy [14] . Moreover, the most common therapy used to treat DLBCL transformed from WM is the combination consisting of rituximab, cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine (Oncovin), and prednisone (R-CHOP) [4] . Unfortunately, in our patient, rituximab could not be administered due to the need to avoid tumor lysis syndrome because of the patient's extremely high tumor burden. The patient died due to the progression of DLBCL, which is the most common cause of death in WM patients with histological transformation [4] . In summary, we demonstrated a rare CD5-positive DLBCL transformed from CD5-negative WM. The DLBCL was highly aggressive and accompanied by BM necrosis. Clinicians should be aware of the co-occurrence of non-Ig-producing aggressive lymphoma, when inexplicable anemia is observed even with good response of low-grade lymphoma to chemotherapy, in addition to paying attention to accompanying massive BM necrosis, which mimics multiple cancer metastases to the bone.
